A Northwestern University-led research team has invented a new method of manufacturing proteins...
- Innovators to watch from TLA’s HealthTech Innovator conference
- Unlocking cell-free protein synthesis: biotech’s next big ticket?
- Can AI reveal complex patterns in biological data?
- Visualising biologics discovery: dealing with complex data
- ASGCT 2018: electroporation-mediated gene delivery for coronary artery disease
Innovators to watch from TLA’s HealthTech Innovator conference
Tech London Advocates and the Health Foundry organised the HealthTech Innovator conference which showcased promising companies working in the pharmaceutical field, whcih are launching new products and are seeking investment. Here is our round-up of the most exciting companies who presented at the event.
Denali and AbCellera to collaborate on treating neurodegenerative disease
US-based biopharmaceutical company Denali Therapeutics has formed an alliance with Canadian therapeutic discovery firm AbCellera Biologics to identify new antibodies to target neurodegenerative diseases.
ASCO 2018: Roche’s polatuzumab vedotin results show promise in DLBCL
Updated Phase II data for Roche’s polatuzumab vedotin in relapsed / refractory (R/R) follicular lymphoma (FL) and diffuse large b-cell lymphoma (DLBCL) patients were presented by Laurie Sehn, MD, during the 2018 ASCO conference.
Unlocking cell-free protein synthesis: biotech’s next big ticket?
A Northwestern University-led research team has invented a new method of manufacturing proteins outside of a cell, an innovation with major implications for biotech. Abi Millar speaks to the team to find out more about the potential of this cell-free protein synthesis platform.
Telstar Presents Versatile Process Analyser Lyosensing
Lyosensing is an in-line process analyser based on the application of a quadrupole mass spectrometer system, a non-invasive technique capable of performing quantitative real-time measurements during freeze-drying processes.
Can AI reveal complex patterns in biological data?
Can artificial intelligence be used to extract genomic data and discover relevant biomarkers? Immune-focused AI technology company CytoReason thinks so. Sally Turner finds out more from co-founder and president David Harel, including how scientists were able to predict who will respond to anti-TNF drugs such as Remicade.
Weibel CDS: Safer, Easier, and Faster Drug Delivery
At the Advanced Technologies and Treatments for Diabetes (ATTD) congress in Paris, Weibel CDS showcased a presentation demonstrating its patient-centric drug delivery products, which help reduce contamination, handling errors, and needle stick injuries when administering injectable drugs.
Fully automated facility for drug discovery to be built in UK
The UK Government has revealed plans to build a fully automated facility at the Rosalind Franklin Institute in Oxfordshire to enable fast, effective and hands-free molecular discovery for new medicines.
Visualising biologics discovery: dealing with complex data
UK-based Dotmatics has announced a new version of its data visualisation tool, Vortex for Bioinformatics, bringing visualisation and informatics tools into the hands of ordinary lab scientists. Abi Millar finds out how the tool can be used.
Phase IIIa Clinical Trial of Oral Semaglutide Completed
Novo Nordisk has announced it has completed the second Phase IIIa trial, PIONEER 2, with oral semaglutide, a once-daily oral formulation of the long-acting GLP-1 analog for the treatment of Type 2 diabetes, which utilises Emisphere Technologies' proprietary Eligen® Technology.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.